Visual field and electrophysiological abnormalities due to vigabatrin

Area of Science:

• Ophthalmology
• Neuroscience
• Pharmacology

Background:

• Vigabatrin is an anti-epileptic drug with a known risk of visual field loss.
• Electrophysiological changes may precede or indicate visual field defects.
• Monitoring the ocular effects of vigabatrin is crucial for patient safety.

Purpose of the Study:

• To investigate electrophysiological changes in patients using vigabatrin.
• To correlate these electrophysiological findings with visual field status.
• To assess the relationship between vigabatrin dosage and ocular changes.

Main Methods:

• Ophthalmological examinations including contrast sensitivity, visual field testing (Humphrey, Esterman, Octopus), and color vision.
• Standardized electroretinography (ERG) and electrooculography (EOG) according to ISCEV standards.
• Correlation analysis between electrophysiological data, visual fields, and daily/cumulative vigabatrin dosages in 29 patients.

Main Results:

• 32% of patients had no visual field constriction, yet 64% showed EOG and/or ERG changes.
• 90% of patients with visual field constriction exhibited EOG and/or ERG abnormalities.
• Significant correlations were found between vigabatrin dosage and visual field defects, as well as ERG rod and cone b-wave amplitude reductions.

Conclusions:

• ERG and EOG testing are sensitive indicators of vigabatrin's direct effect on the outer retina.
• Electrophysiological tests may offer a more sensitive method for monitoring vigabatrin's ocular toxicity than visual field testing alone.
• These findings highlight the importance of electrophysiological monitoring in patients treated with vigabatrin.